
Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.
Coadministration of zuranolone with a standard antidepressant yields positive outcomes.
Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.
To read more about this study, see:
Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.